Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3. This drug was developed by Innate Pharma...
4 KB (268 words) - 05:29, 9 June 2024
Golimumab Ianalumab† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab...
38 KB (4,316 words) - 10:24, 26 August 2024
satetraxetan mab mouse CD37 cancer Lintuzumab mab humanized CD33 cancer Lirilumab mab human KIR2D solid and hematological cancers Lodelcizumab mab humanized...
136 KB (4,020 words) - 06:13, 27 September 2024
Fostemsavir (BMS-663068) – approved in the United States in July 2020 Lirilumab (BMS-986015) Lulizumab pegol (BMS-931699) – phase II Bristol-Myers Squibb...
96 KB (7,620 words) - 18:57, 12 September 2024
is KIR2DL4. Innate and Bristol Myers are testing monoclonal antibody Lirilumab, which binds to KIR2DL1 (CD158A) and KIR2DL2/3, thus blocking the interaction...
96 KB (467 words) - 19:33, 6 August 2024
molecules on Natural Killer cells. Bristol-Myers Squibb is working on Lirilumab, a monoclonal antibody to KIR. LAG3: short for Lymphocyte Activation Gene-3...
31 KB (3,467 words) - 01:27, 25 June 2024
is a human monoclonal antibody that binds to KIR2DL1/2L3. Very similar Lirilumab is intended for the treatment of cancers e.g. leukemia. The Killer-cell...
36 KB (4,273 words) - 17:48, 19 August 2024
Golimumab Ianalumab† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab...
2 KB (87 words) - 01:28, 30 May 2023